CRF Health Introduces eCOA Solution for Oncology Trials

Article

Applied Clinical Trials

 

Plymouth Meeting, PA – August 10, 2015:  CRF Health, the leading global provider of electronic Clinical  Outcome Assessment (eCOA) solutions for the life sciences industry, introduces a complete TrialMax® eCOA solution specifically for oncology clinical trials. Developed based on CRF Health's experience of delivering over 100 successful global oncology studies, the solution streamlines data collection by    combining an eCOA capture system with intuitive site and patient management tools. Reporting concomitant medication data is also simplified, enabling sponsors to collect complete data while reducing patient and investigator burden.

The length, complexity and increased data demands of oncology trials places a considerable burden on patients, sites and study teams alike. The identification of concomitant medication also brings its own challenges. CRF Health has incorporated its new TrialMax ConMed™ solution into the platform, allowing patients to easily report concomitant medication taken during a trial in real-time and deliver this data to investigators. This not only helps sponsors in identifying which side effects are related to the study drug, but minimizes risk for resulting regulatory submissions.

"Busy site visits and sick patients taking multiple medications means that both investigators and patients may find it difficult to keep track of their condition in a way that meets the requirements of a trial's protocol. We have created this solution to support sponsors with the common problems they face in oncology trials and to collect data which shows the efficacy of the drug in near to real-time”, comments Rauha Tulkki-Wilke, VP Product and Service Management at CRF Health. “In doing so, we have been able to reduce burden on patients and site staff, resulting in improved retention and adherence, two of the biggest challenges in oncology studies.”

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.